UNSPSC 51422505: Amebucort

This classification denotes a therapeutic glucocorticoid with the molecular formula C28H40O7, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7YRF8G0G0F, chemically known as 11 beta,17,21-trihydroxy-6 alpha-methylpregn-4-ene-3,20-dione 21-acetate 17-butyrate but generally known as amebucort, which bears US NIH Compound Identifier 3086167. European Medicines Agency schedules Amebucort in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05405MIG.

UNSPSC 51422505 Amebucort is a Commodity code that covers specific pharmaceutical products, but recent state and local solicitation activity under this code shows minimal relevance to the nominal classification. The two recent opportunities posted show purchasing of naloxone and drug deactivation systems (Seminole County, Florida) and a request for information on direct-to-manufacturer prescription programs (Texas Health and Human Services Commission), neither of which align with amebucort's pharmaceutical scope. State and local governments have not posted solicitations specifically naming amebucort in the recent opportunities block, and the code appears to see little active procurement activity at the state and local level.

Seminole County, Florida issued an IFB on June 30, 2026, for naloxone and safe drug deactivation systems with a response deadline of July 26, 2023, requiring quarterly deliveries to the Seminole County Community Health Building in Sanford. Texas HHS issued an RFI on April 3, 2026, to gather market intelligence on direct-to-manufacturer prescription programs without a formal competitive timeline. The mismatch between the code's nominal product and the actual solicitations posted suggests this Commodity code does not represent a current procurement avenue for vendors serving state and local health systems and departments.